|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have recently examined the MAPT locus in progressive supranuclear palsy and found that a haplotype (H1c) on the background of the well-described H1 clade is associated with PSP.
|
16000317 |
2005 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To review the clinical and molecular features of non-Alzheimer's disease (non-AD) dementias, focusing on disorders associated with tau pathology (that is, frontotemporal lobar degeneration [FTLD], corticobasal ganglionic degeneration [CBD], and progressive supranuclear palsy [PSP]) or on disorders with synuclein pathology (that is, dementia with Lewy bodies [DLB] and multisystem atrophy [MSA]).
|
15101498 |
2004 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis.
|
14502653 |
2003 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
Animal models suggest that early markers of Sjögren syndrome (EMS)-antibodies against salivary protein 1, parotid secretory protein, and carbonic anhydrase 6 (CA6)-are more accurate signals of early Sjögren when compared with classic markers (anti-Ro and anti-La).
|
31634227 |
2020 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
Recently, the presence of novel tissue specific autoantibodies (TSAs), SP-1, CA6, and PSP, has been observed in the early stages of SS.
|
30572137 |
2019 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
In the Penn SICCA cohort, SP-1 IgM and PSP IgA autoantibodies were more prevalent in the serum of SS-related dry eye participants compared with those without SS.
|
31517725 |
2019 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
The SS group had a higher prevalence of SP-1 autoantibodies than the group without SS or other autoimmune diseases (33% vs. 19%; P = 0.02) but had no difference in carbonic anhydrase 6 (P = 0.31) or parotid secretory protein autoantibodies (P = 0.33).
|
30161055 |
2018 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
To investigate the value of 3 novel autoantibodies [salivary protein 1 (SP1), carbonic anhydrase 6 (CA6), and parotid secretory protein (PSP)] in differentiating Sjögren's syndrome (SS)-related dry eye from non-SS dry eye.
|
29504954 |
2018 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
Several newly-identified biomarkers for SS include autoantibodies to proteins specific to the salivary and lacrimal glands [SP-1 (salivary gland protein-1), PSP (parotid secretory protein), CA-6 (carbonic anhydrase VI)].
|
28283891 |
2017 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
Antibodies to SP-1, CA6 and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La.
|
23123440 |
2012 |
|
Parkinson Disease
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Using a PSP genetic risk score (GRS), we showed that the genetic risk burden in the EOPSP (mean z-score, 0.59) and LOPSP (mean z-score, 0.48) groups was significantly higher (P < 0.05) when compared with the PD group (mean z-score, -0.08).
|
31299107 |
2019 |
|
Parkinson Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
The MRPI differentiated patients with PSP-P from those with PD with sensitivity and specificity of 73.5% and 98.1%, respectively, while the MRPI 2.0 showed higher sensitivity (100%) and similar specificity (94.3%) in differentiating between these two groups.
|
30068492 |
2018 |
|
Parkinson Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
We aimed to assess whether a combined analysis of dopamine transporter (DAT)- and perfusion-SPECT images (or either) could: (1) distinguish atypical parkinsonian syndromes (APS) from Lewy body diseases (LBD; majority Parkinson disease [PD]), and (2) differentiate among APS subgroups (progressive supranuclear palsy [PSP], corticobasal syndrome [CBS], and multiple system atrophy [MSA]).
|
29157745 |
2018 |
|
Parkinson Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
Observer-independent analysis of microstructural integrity within the dentatorubrothalamic tract in combination with assessments of gait and postural stability differentiate PSP-P from PSP-RS and PD in early to moderately advanced stages.
|
29463454 |
2018 |
|
Parkinson Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
Midbrain atrophy progresses differentially in patients with PSP-RS, PSP-P, and PD.
|
27614955 |
2017 |
|
Parkinson Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
201 Patients with PD were studied.The sample was supplemented with 29 patients diagnosed with MSA-P (according to the criteria established by the American Academy of Neurology) and 17 with PSP (according to the criteria established by the NINDS-SPSP International Workshop).
|
20083340 |
2010 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Neurogranin was decreased in PD, PD with dementia, MSA, and PSP compared to controls and Alzheimer's disease.
|
31837067 |
2020 |
|
Alzheimer's Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
<b>Objectives:</b> The present study is geared to learning about the patterns of tau seeding and cells involved following unilateral inoculation in the corpus callosum of homogenates from sporadic Alzheimer's disease (AD), primary age-related tauopathy (PART: neuronal 4Rtau and 3Rtau), pure aging-related tau astrogliopathy (ARTAG: astroglial 4Rtau with thorn-shaped astrocytes TSAs), globular glial tauopathy (GGT: 4Rtau with neuronal tau and specific tau inclusions in astrocytes and oligodendrocytes, GAIs and GOIs, respectively), progressive supranuclear palsy (PSP: 4Rtau with neuronal inclusions, tufted astrocytes and coiled bodies), Pick's disease (PiD: 3Rtau with characteristic Pick bodies in neurons and tau containing fibrillar astrocytes), and frontotemporal lobar degeneration linked to P301L mutation (FTLD-P301L: 4Rtau familial tauopathy).
|
31191295 |
2019 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
N-224 tau concentrations in PSP and CBS were significantly lower than in AD (p < 0.0001) and did not correlate to t-tau and p-tau.
|
30547227 |
2019 |
|
Tauopathies
|
0.050 |
GeneticVariation
|
group |
BEFREE |
<b>Objectives:</b> The present study is geared to learning about the patterns of tau seeding and cells involved following unilateral inoculation in the corpus callosum of homogenates from sporadic Alzheimer's disease (AD), primary age-related tauopathy (PART: neuronal 4Rtau and 3Rtau), pure aging-related tau astrogliopathy (ARTAG: astroglial 4Rtau with thorn-shaped astrocytes TSAs), globular glial tauopathy (GGT: 4Rtau with neuronal tau and specific tau inclusions in astrocytes and oligodendrocytes, GAIs and GOIs, respectively), progressive supranuclear palsy (PSP: 4Rtau with neuronal inclusions, tufted astrocytes and coiled bodies), Pick's disease (PiD: 3Rtau with characteristic Pick bodies in neurons and tau containing fibrillar astrocytes), and frontotemporal lobar degeneration linked to P301L mutation (FTLD-P301L: 4Rtau familial tauopathy).
|
31191295 |
2019 |
|
Tauopathies
|
0.050 |
Biomarker
|
group |
BEFREE |
PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes.
|
28500751 |
2017 |
|
Tauopathies
|
0.050 |
Biomarker
|
group |
BEFREE |
Over two dozen mutations in the gene encoding the microtubule associated protein tau cause a variety of neurodegenerative dementias known as tauopathies, including frontotemporal dementia (FTD), PSP, CBD and Pick's disease.
|
24086739 |
2013 |
|
Alzheimer's Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
However, although there are currently only limited data available, AgD seems to be clinically distinct from PSP and CBD and shares rather features of (mild) AD or other forms of 'limbic' dementias, among them senile dementia with tangles and the localized form of AD.
|
15641585 |
2004 |
|
Tauopathies
|
0.050 |
Biomarker
|
group |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |
|
Tauopathies
|
0.050 |
Biomarker
|
group |
BEFREE |
Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis.
|
14502653 |
2003 |